Tag: 104-54-1 IC50

Ceftriaxone, an FDA-approved third-generation cephalosporin antibiotic, has antimicrobial activity against both gram-positive and gram-negative organisms. to clinical trials while resulting in only a 104-54-1 IC50 few drugs being proven effective and thereby gaining approval. More than $800 million is the estimated cost with 10C17 years required for developing a drug (1). Reverse side effects, usually…